About GRAM domain-containing protein 2B
GRAM domain-containing protein 2B (GRAMD2B) is a protein
from Homo sapiens identified by UniProt accession
Q96HH9, 432 residues long.
MolForge cross-references it against 0 known binders and
93 disease associations.
Target properties
| Protein name | GRAM domain-containing protein 2B |
| UniProt accession | Q96HH9 |
| Gene | GRAMD2B |
| Organism | Homo sapiens |
| Length | 432 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (93)
Diseases linked to this target (Open Targets).
- diabetic nephropathy · score 0.27
- type 2 diabetes mellitus · score 0.27
- hematocrit · score 0.24
- hemoglobin measurement · score 0.23
- protein measurement · score 0.18
- neurofibrillary tangles measurement · score 0.17
- visceral adipose tissue measurement · score 0.16
- body mass index · score 0.16
- hypopituitarism · score 0.16
- cognitive decline measurement · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96HH9-F1 | alphafold | PREDICTED | 63.17 | — |
Amino-acid sequence (432 residues)
MTELQQDVED TKPAKVLGKR ESKLGSAHSE AENGVEEKKK ACRSPTAQSP TPSVEADSPD QKKIISLWSK SSFDGASLAS DKNDCKTESK NDPKTERKKS SSSSQYKANM HFHKLFLSVP TEEPLKQSFT CALQKEILYQ GKLFVSENWI CFHSKVFGKD TKISIPAFSV TLIKKTKTAL LVPNALIIAT VTDRYIFVSL LSRDSTYKLL KSVCGHLENT SVGNSPNPSS AENSFRADRP SSLPLDFNDE FSDLDGVVQQ RRQDMEGYSS SGSQTPESEN SRDFHATESQ TVLNVSKGEA KPTRADAHVN RVPEGKAKSL PVQGLSETVG ILHKVKSQKC PMLHHILIFY AIVVCALIIS TFYMRYRINT LEEQLGLLTS IVDTHNTEQA APSGLRSQVQ FNVEVLCQEL TANIVKLEKI QNNLQKLLEN GD
Explore GRAM domain-containing protein 2B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets